Kyowa Kirin news

Latest news

• 
  Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab (opens in a new tab)

  Hospital Management · Sep 30, 2026

• 
  Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America (opens in a new tab)

  Business Wire · Sep 29, 2026

• 
  Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab) (opens in a new tab)

  Sep 29, 2026

• 
  Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback? (opens in a new tab)

  Simply Wall St. · Sep 25, 2026

• Tech, Oil Concerns Cramp Asian Stock Markets (opens in a new tab)

  Sep 9, 2026

• Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC (opens in a new tab)

  Sep 9, 2026

• Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President (opens in a new tab)

  Sep 2, 2026

• Mid-cap biotechs join Trump’s latest round of drug pricing deals (opens in a new tab)

  Sep 1, 2026

• Trump lines up MFN deals with nine mid-size pharmas on drug pricing push (opens in a new tab)

  Sep 1, 2026

• $19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers (opens in a new tab)

  Aug 31, 2026

• Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans (opens in a new tab)

  GlobeNewswire · Aug 31, 2026

• 
  Is Cognizant (CTSH) Quietly Redefining Its Automation Edge With Kyowa Kirin’s AI R&D Deal? (opens in a new tab)

  Simply Wall St. · Aug 26, 2026

• Cognizant (CTSH) Stock May Trade At A 44% Discount Despite Fresh AI Contract Pressure (opens in a new tab)

  Aug 26, 2026

• Cognizant and Benchling Selected as Partners to Accelerate Kyowa Kirin's R&D (opens in a new tab)

  Aug 17, 2026

• Sanofi halts development of troubled immune drug in eczema (opens in a new tab)

  Jul 24, 2026

• 
  European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union (opens in a new tab)

  Business Wire · Jul 21, 2026

• Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight (opens in a new tab)

  Jul 9, 2026

• Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme (opens in a new tab)

  Jun 30, 2026

• FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience (opens in a new tab)

  GlobeNewswire · Jun 30, 2026

• 
  Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL (opens in a new tab)

  GlobeNewswire · Jun 10, 2026

• 
  Romiplate Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan (opens in a new tab)

  GlobeNewswire · May 15, 2026

• 
  Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress (opens in a new tab)

  GlobeNewswire · May 12, 2026

• 
  Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML (opens in a new tab)

  GlobeNewswire · Apr 24, 2026